#ASH17: Ab­b­Vie, Roche boast stel­lar PhI­II leukemia da­ta for a “break­through” com­bo with block­buster am­bi­tions

Ab­b­Vie and Roche rolled out the full bat­tery of im­pres­sivePhase III da­ta for their com­bi­na­tion of Ven­clex­ta and Rit­ux­an, mak­ing a case at ASH that they’ve nailed down all the da­ta need­ed to prove it should be used for sec­ond line cas­es of chron­ic lym­pho­cyt­ic leukemia.

And the soon­er the bet­ter.

Their matchup hand­i­ly beat out the stan­dard CLL com­bo of ben­damus­tine and Rit­ux­an on both pro­gres­sion-free sur­vival as well as com­plete re­spons­es. The 24-month PFS rate hit 84.9% for the Ab­b­Vie $AB­BV/Roche $RHH­BY com­bo against 36.3% for chemo/Rit­ux­an. And the com­plete re­sponse rate — no sign of the dis­ease — reg­is­tered at 26.8% against 8.2%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER